Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EP Vantage PD-1/PD-L1 Combination Therapies

EP Vantage PD-1/PD-L1 Combination Therapies EP Vantage PD-1/PD-L1 Combination Therapies EP Vantage PD-1/PD-L1 Combination Therapies

Download Report

PD-1/PD-L1 Combinations Drive the Development of New Immunotherapies

The immuno-oncology agents Keytruda and Opdivo have already transformed the cancer care landscape.

Now specialists are pairing them with approved or experimental agents to improve on their already impressive efficacy, according to the “PD-1/PD-L1 Combination Therapies” report.

Key findings of the PD-1/PD-L1 Combination Therapies report include:

  • More than half of the agents paired with PD-1 and PD-L1 projects are small molecules, chemotherapies and established drugs
  • Yervoy is the most widely studied monoclonal antibody combination agent
  • Lung cancer and melanoma remain the two most popular indications for combination products
  • A number of products including atezolizumab and durvalumab are already being tested in combination, even before achieving approval from the FDA or European Medicines Agency
  • Older therapies such as oncolytic viruses and vaccines that have so far disappointed as monotherapies might benefit from the combination approach

Press Release


Confirm your details on form below to download this report